Action Angle - AGL

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

14,50

Prix Achat

14,00

Prix Vente

15,00

Volume échangé

1 867 603

14,50 Fourchette du Jour 15,25

7,25 Plage de 52 semaines 25,00

Cap du marché

46,783M

Clôture Veille

15,00

Ouverture

15,25

Dernière Transaction

1005

14.5685

(O)

Dernière heure de transaction

Volume financier

274 538p

VWAP

14,70

Volume moyen (3 m)

1 552 510

Actions en circulation

322 641 668

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,32

Bénéfice par action (BPA)

-0,06

Chiffre d'affairess

2,19M

Bénéfice net

-20,13M

Secteur

Business Services, Nec

Industrie

Business Consulting

Site Web

www.angleplc.com

Siège social

Guildford, Gbr

Fondé

2003

Angle Plc est coté dans le secteur Business Services de la London Stock Exchange avec le ticker AGL. Le dernier cours de clôture d'Angle était de 15,00p. Au cours de la dernière année, les actions de Angle ont été négociées dans une fourchette de prix de 7,25p à 25,00p.

Angle compte actuellement 322 641 668 actions en circulation. La capitalisation boursière d'Angle est de £48,40 million. Angle a un ratio cours/bénéfice (ratio PE) de -2.32.

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour ce ...

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle PLC 29 January 2025 For immediate release 29 January 2025 ANGLE plc ("the Company") NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing...

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC on Thursday said it expected losses to have narrowed in 2024, but its share price suggested lingering marke ...

Angle PLC Trading Update

Angle PLC 23 January 2025 For immediate release 23 January 2025 ANGLE plc ("the Company") TRADING UPDATE Revenue for 2024 expected to be up 31% Lower cost base going into 2025 with a...

Angle stock surges as firm showcases new assay products

Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patien ...

Angle notes use of Parsortix system in treatment resistance study

Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung canc ...

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported b ...

Angle PLC Half-year Report

Angle PLC 26 September 2024 For Immediate Release 26 September 2024 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY...

Angle PLC Exclusive agreement for DNA NGS panel

Angle PLC 23 September 2024 For immediate release 23 September 2024 ANGLE plc ("the Company") ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE Option for...

IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals

ford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a ...

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour ce ...

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle PLC 29 January 2025 For immediate release 29 January 2025 ANGLE plc ("the Company") NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing...

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC on Thursday said it expected losses to have narrowed in 2024, but its share price suggested lingering marke ...

Angle PLC Trading Update

Angle PLC 23 January 2025 For immediate release 23 January 2025 ANGLE plc ("the Company") TRADING UPDATE Revenue for 2024 expected to be up 31% Lower cost base going into 2025 with a...

Angle stock surges as firm showcases new assay products

Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patien ...

Angle notes use of Parsortix system in treatment resistance study

Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung canc ...

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported b ...

Angle PLC Half-year Report

Angle PLC 26 September 2024 For Immediate Release 26 September 2024 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.25	9.43396226415	13.25	16.25	11.25	4586953	14.02562266	DE
4	4.25	41.4634146341	10.25	16.25	10.25	1785590	13.25798931	DE
12	6.5	81.25	8	16.25	7.75	1552510	11.58315088	DE
26	0.5	3.57142857143	14	16.25	7.25	1206198	11.03417862	DE
52	-1.75	-10.7692307692	16.25	25	7.25	1429029	14.10118371	DE
156	-101.5	-87.5	116	163.5	7.25	1585716	29.76724334	DE
260	-58.5	-80.1369863014	73	163.5	7.25	1240252	41.93756019	DE

AGL - Frequently Asked Questions (FAQ)

What is the current Angle share price?

The current share price of Angle is 14,50p

How many Angle shares are in issue?

Angle has 322 641 668 shares in issue

What is the market cap of Angle?

The market capitalisation of Angle is GBP 48,4M

What is the 1 year trading range for Angle share price?

Angle has traded in the range of 7,25p to 25,00p during the past year

What is the PE ratio of Angle?

The price to earnings ratio of Angle is -2,32

What is the cash to sales ratio of Angle?

The cash to sales ratio of Angle is 21,32

What is the reporting currency for Angle?

Angle reports financial results in GBP

What is the latest annual turnover for Angle?

The latest annual turnover of Angle is GBP 2,19M

What is the latest annual profit for Angle?

The latest annual profit of Angle is GBP -20,13M

What is the registered address of Angle?

The registered address for Angle is 10 NUGENT ROAD, THE SURREY RESEARCH PARK, GUILDFORD, GU2 7AF

What is the Angle website address?

The website address for Angle is www.angleplc.com

Which industry sector does Angle operate in?

Angle operates in the BUSINESS CONSULTING sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
GILDGuild Esports Plc	0,075p (66,67%)	158,2M
MSMNMosman Oil And Gas Limited	0,038p (52,00%)	2,3B
MODER8 Capital Investments Plc	2,10p (40,00%)	7,75M
LENDSancus Lending Group Limited	0,60p (33,33%)	2,2M
KMKKromek Group Plc	6,65p (25,47%)	41,88M
FUMFutura Medical Plc	16,98p (-45,23%)	8,72M
RCDORicardo Plc	263,00p (-25,28%)	4,42M
PEGPetards Group Plc	6,50p (-18,75%)	1,16M
SCGLSealand Capital Galaxy Limited	6,50p (-14,47%)	6,21M
SIVSivota Plc	3,00p (-14,29%)	7,5k
MSMNMosman Oil And Gas Limited	0,038p (52,00%)	2,3B
DKEDukemount Capital Plc	0,055p (22,22%)	1,4B
EMEEmpyrean Energy Plc	0,115p (4,55%)	917,03M
TRPTower Resources Plc	0,0295p (3,51%)	470,89M
DGIDg Innovate Plc	0,0155p (-8,82%)	344,08M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Angle Plc (AGL)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Angle Plc

AGL Dernières nouvelles

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC Trading Update

Angle stock surges as firm showcases new assay products

Angle notes use of Parsortix system in treatment resistance study

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

Angle PLC Half-year Report

Angle PLC Exclusive agreement for DNA NGS panel

IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals

Angle reports breakthrough in dual cancer DNA analysis

Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay

Angle fails to win market confidence despite narrowing loss in 2024

Angle PLC Trading Update

Angle stock surges as firm showcases new assay products

Angle notes use of Parsortix system in treatment resistance study

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

Angle PLC Half-year Report

AGL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Angle Plc (AGL) Cours

Angle Plc (AGL)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Angle Plc

AGL Dernières nouvelles

AGL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités